课题基金 / 基金详情

项目摘要

项目成果

STEPHEN Lev HOFFMAN的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 Sanaria的恶性疟原虫(PF)子孢子(SPZ)疫苗开发计划正在接受全球 支持。PfSPZ疫苗(辐射减毒PfSPZ)或PfSPZ-CVAc(PfSPZ化学预防)的试验 年开始通过直接静脉接种(DVI)接种疫苗,包括约1,500名成人给婴儿接种 2015年12月(坦桑尼亚、美国)或将于2016年初在马里、肯尼亚(约500名婴儿)、加纳、 赤道几内亚、德国和另外3个美国网站。这些试验将评估3剂、2剂或1剂方案,如 最后一次给药后9周,用三次给药方案建立了100%的保护性效果。保护性的 对控制疟疾感染(CHMI)的疗效已被证明至少持续了一年,以及 在马里对抗异质性肺炎毒株的强烈自然传播至少6个月。PfSPZ 疫苗和PfSPZ-CVAc由PF NF54株的PfSPZ组成。短期保护(3周) 对带有Pf7G8寄生虫的异源(不同于疫苗株)CHMI的PfSPZ疫苗免疫效果为80%, 但是,尽管寄生虫血症的发病明显延迟,但6个月的无菌保护效果仅为10%。 Sanaria正在采取两种方法来提高对异源/异质菌株的保护效力。 第一个是增加PfSPZ(NF54)的每次免疫剂量,假设这将 扩大和加强针对共享显性和亚显性的保护性免疫反应 表位。上述所有试验都采用了这一方法。第二种,也可能是更有效的方法 将来自不同PF毒株的PfSPZ结合在同一疫苗中。我们对基因组序列的分析 数据、预测的蛋白质组和预测的T细胞表位表明,使用两种PF菌株应该是 足够了。这个项目填补了一个重要的空白。我们有来自VRC,NIAID,NIH的资金来进行临床试验 多价PfSPZ疫苗,但需要资金来制造、表征和释放多价PfSPZ疫苗 疫苗,并导航启动试验所需的监管/临床事务途径。在此阶段IIB SBIR项目,我们建议,1)制造和QC释放氯喹敏感的PfSPZ挑战剂 非洲PF克隆(NF166),可用于CHMI研究,并作为多菌株PfSPZ-CVac的组成部分; 2)基于巴西PF克隆(7G8)和PfSPZ疫苗(NF54)的PfSPZ疫苗的研制和释放 用于双株/克隆PfSPZ疫苗组合;3)制造和发布PfSPZ挑战赛(7G8)和 PfSPZ挑战(NF54)双菌株组合PfSPZ-CVac;以及4)结束阶段2会议 与FDA一起提出并最终确定将CHMI第三阶段试验与PfSPZ挑战(NF54、7G8、 NF135.C10和NF166),以取代第三阶段现场试验,以确定疫苗的保护效力。成功 这将使为旅行者/军人发放PfSPZ疫苗许可证的时间至少缩短一年,并节省5000万美元。它 还将促进更快地开发所有红细胞前期疫苗,旨在提供高 旅行者接种疫苗所需的水平(80%)保护,军事和消灭运动。
英文摘要
ABSTRACT Sanaria’s Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines development program is receiving global support. Trials of PfSPZ Vaccine (radiation attenuated PfSPZ) or PfSPZ-CVac (PfSPZ Chemoprophylaxis Vaccine) administered by direct venous inoculation (DVI), including ~1,500 adults to infants were initiated in December 2015 (Tanzania, U.S.) or will be initiated in early 2016 in Mali, Kenya (~500 infants), Ghana, Equatorial Guinea, Germany and 3 additional U.S. sites. These trials will assess 3-, 2- or 1-dose regimens, as 100% protective efficacy at 9 weeks after last dose has been established with a 3-dose regimen. Protective efficacy has been shown to be durable against controlled malaria infection (CHMI) for at least a year, and against intense natural transmission in Mali of heterogeneous strains of Pf for at least 6 months. PfSPZ Vaccine and PfSPZ-CVac are comprised of PfSPZ of the NF54 strain of Pf. Short-term protection (3 weeks) by PfSPZ Vaccine against a heterologous (different from the vaccine strain) CHMI with Pf7G8 parasites was 80%, but despite a significant delay in onset of parasitemia, 6 month sterile protective efficacy was only 10%. Sanaria is taking two approaches to improving protective efficacy against heterologous/heterogeneous strains. The 1st is to increase the dose of PfSPZ (NF54) per immunization based on the hypothesis that this will broaden and strengthen the protective immune responses against shared dominant and sub-dominant epitopes. All of the trials described above utilize this approach. The 2nd and potentially more efficient approach will be to combine PfSPZ from different strains of Pf in the same vaccine. Our analysis of genomic sequence data, predicted proteomes, and predicted T cell epitopes indicates that using two strains of Pf should be sufficient. This project fills an important gap. We have funding from VRC, NIAID, NIH to conduct a clinical trial of a multivalent PfSPZ vaccine, but require the funds to manufacture, characterize, and release the multi-valent vaccine, and to navigate the regulatory/clinical affairs pathways required to initiate the trial. In this Phase IIB SBIR project, we propose to, 1) Manufacture and QC release chloroquine sensitive PfSPZ Challenge of a W African Pf clone (NF166) that can be used for CHMI studies and as a component of a multi-strain PfSPZ-CVac; 2) Manufacture and release PfSPZ Vaccine based on the Brazilian Pf clone (7G8) and PfSPZ Vaccine (NF54) for a two-strain/clone PfSPZ Vaccine combination; 3) Manufacture and release PfSPZ Challenge (7G8) and PfSPZ Challenge (NF54) for a two-strain combination PfSPZ-CVac; and 4) Conduct an end of phase 2 meeting with FDA to propose and finalize a plan for using phase 3 CHMI trials with PfSPZ Challenge (NF54, 7G8, NF135.C10, and NF166) to replace phase 3 field trials to establish protective efficacy of the vaccines. Success will reduce the time to licensure of a PfSPZ vaccine for travelers/military by at least a year and save > $50M. It will also facilitate more rapid development of all pre-erythrocytic stage vaccines intended to provide the high level (>80%) protection required for a vaccine for travelers, military, and elimination campaigns.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro
  • 批准号:
    10761373
  • 项目类别:
  • 资助金额:
    $28.22万
  • 财政年份:
    2023
  • 负责人:
    STEPHEN Lev HOFFMAN
  • 依托单位:
Progressing PfSPZ vaccines for malaria to licensure and commercialization
  • 批准号:
    10602357
  • 项目类别:
  • 资助金额:
    $99.99万
  • 财政年份:
    2023
  • 负责人:
    STEPHEN Lev HOFFMAN
  • 依托单位:
PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria
  • 批准号:
    10406059
  • 项目类别:
  • 资助金额:
    $98.88万
  • 财政年份:
    2022
  • 负责人:
    STEPHEN Lev HOFFMAN
  • 依托单位:
Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray
  • 批准号:
    10156019
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    STEPHEN Lev HOFFMAN
  • 依托单位:
海外基金